In Section C, contributors will acquire ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment right up until disorder progression or maybe the contributors are unable to tolerate the study drugs. For all flow cytometry experiments, 10,000 cells for every replicate were https://abbv-744-combination-ther69135.blogrelation.com/38162983/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained